- Home
- SYBX vs CWD Comparison
SYBX vs CWD Comparison
Compare SYBX & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- CWD
- Stock Information
- Founded
- SYBX N/A
- CWD 2009
- Country
- SYBX United States
- CWD United States
- Employees
- SYBX N/A
- CWD N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- CWD Real Estate
- Sector
- SYBX Health Care
- CWD Finance
- Exchange
- SYBX Nasdaq
- CWD Nasdaq
- Market Cap
- SYBX 11.8M
- CWD 12.1M
- IPO Year
- SYBX N/A
- CWD 2023
- Fundamental
- Price
- SYBX $1.16
- CWD $0.24
- Analyst Decision
- SYBX
- CWD
- Analyst Count
- SYBX 0
- CWD 0
- Target Price
- SYBX N/A
- CWD N/A
- AVG Volume (30 Days)
- SYBX 13.5K
- CWD 786.9K
- Earning Date
- SYBX 05-13-2025
- CWD 05-08-2025
- Dividend Yield
- SYBX N/A
- CWD N/A
- EPS Growth
- SYBX N/A
- CWD N/A
- EPS
- SYBX N/A
- CWD N/A
- Revenue
- SYBX $8,000.00
- CWD $51,119,000.00
- Revenue This Year
- SYBX N/A
- CWD N/A
- Revenue Next Year
- SYBX N/A
- CWD $35.72
- P/E Ratio
- SYBX N/A
- CWD N/A
- Revenue Growth
- SYBX N/A
- CWD N/A
- 52 Week Low
- SYBX $0.90
- CWD $0.25
- 52 Week High
- SYBX $1.96
- CWD $1.04
- Technical
- Relative Strength Index (RSI)
- SYBX 50.18
- CWD 21.91
- Support Level
- SYBX $1.00
- CWD $0.20
- Resistance Level
- SYBX $1.10
- CWD $0.57
- Average True Range (ATR)
- SYBX 0.10
- CWD 0.07
- MACD
- SYBX 0.01
- CWD -0.03
- Stochastic Oscillator
- SYBX 84.64
- CWD 7.38
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.